Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LY3463251 in healthy and overweight subjects
NCT03764774Phase 1Terminated
- Sponsor
- Eli Lilly and Company
- Start
- Dec 2018
- Primary completion
- Dec 2020
- Modality
- Fc Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of LY3463251 (14 arms), sponsored by Eli Lilly and Company. Primary endpoint: Adverse Events. Started Dec 2018; status: terminated.
02
Drugs
LY3463251
Beyond the preview
Go deeper on NCT03764774.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03764774.